Genflow Biosciences Reports Positive Safety Data from Second Administration of SIRT6 Gene Therapy in Elderly Dogs
Key Insights
Genflow Biosciences (search) successfully completed the second administration of its SIRT6 (search)-centenarian gene therapy in a randomized controlled trial involving 28 beagles aged 10 years and older, demonstrating excellent safety and tolerability.
The proprietary gene therapy, sourced from human centenarians, targets age-related decline (search) through DNA repair and metabolic regulation mechanisms, with no adverse effects observed in either administration.
The company aims to leverage this gene therapy platform to enter the multi-billion-dollar animal health market, targeting improved healthspan and lifespan in companion and livestock animals.
Genflow Biosciences (search) Plc has reported encouraging safety data from the second administration of its proprietary SIRT6 (search)-centenarian gene therapy in elderly dogs, marking a significant milestone in the company's proof-of-concept clinical trial. The London-based biotechnology firm, which describes itself as the only publicly listed longevity company in Europe, administered the therapy to 28 beagles aged 10 years and older as part of its ongoing randomized controlled study.
Strong Safety Profile Maintained Across Administrations
The gene therapy demonstrated an excellent safety and tolerability profile during the second administration, consistent with results from the initial treatment in March. During the first administration, recipients received three different modalities of SIRT6 (search) gene therapy with no ill or adverse effects observed, while control animals remained untreated. The successful repeat administration underscores the robustness of Genflow's gene therapy platform and its potential for broader applications.
The dogs are currently in a follow-up period expected to conclude in January 2026, allowing researchers to monitor long-term effects and gather additional efficacy data.
SIRT6 Gene Therapy Mechanism and Potential
The SIRT6 (search) gene, sourced from human centenarians, plays a vital role in DNA repair, metabolic regulation, and resistance to age-related decline (search). This unique gene variant forms the foundation of Genflow's approach to introducing longevity-based treatments into the animal health market. The therapy targets improved healthspan, vitality, and lifespan in both companion and livestock animals.
Dr. Eric Leire, Chief Executive Officer of Genflow Biosciences (search), expressed optimism about the results and market potential. "We're very encouraged by the continued safety validation of our SIRT6 (search) therapy and by the strong engagement we're seeing from established players in the animal health industry," Leire commented. "The animal health market represents an attractive near-term commercial opportunity for Genflow, complementing our core human longevity programs while showcasing the broader potential of our gene therapy platform."
Commercial Strategy and Market Opportunity
The positive safety data positions Genflow to pursue opportunities in the multi-billion-dollar global animal health market. The company views this sector as an attractive near-term commercial opportunity that complements its core human longevity programs while demonstrating the broader applicability of its gene therapy platform.
With safety confirmed through repeat administration, Genflow plans to continue advancing its animal health initiative toward the next stage of clinical evaluation and partnership development. The company has noted strong engagement from established players in the animal health industry, suggesting potential collaboration opportunities as the program progresses.
The market responded positively to the announcement, with Genflow Biosciences (search) shares rising 4.8% to 2.20 pence in London trading following the data release.